Literature DB >> 25617196

Hepatitis C drug affordability.

Mohga Kamal-Yanni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25617196     DOI： 10.1016/S2214-109X(14)70365-1

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN： 2214-109X            Impact factor:   26.763


× No keyword cloud information.
  13 in total

Review 1.  Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.

Authors:  Ameer Abutaleb; Shyam Kottilil; Eleanor Wilson
Journal:  Hepatol Int       Date:  2018-05-29       Impact factor: 6.047

Review 2.  Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

Authors:  Andrew J Muir; Susanna Naggie
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-17       Impact factor: 11.382

3.  Hepatitis C eradication: A long way to go.

Authors:  Yasir Waheed
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

4.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

Review 5.  Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals.

Authors:  Khashayar Hesamizadeh; Heidar Sharafi; Mohammad Saeid Rezaee-Zavareh; Bita Behnava; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-04-18       Impact factor: 0.660

6.  Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4.

Authors:  Hanan H Rizk; Nadia M Hamdy; Nadia L Al-Ansari; Hala O El-Mesallamy
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

7.  Hepatitis C virus and HIV infections among people who inject drugs in the Middle East and North Africa: a neglected public health burden?

Authors:  Ghina R Mumtaz; Helen A Weiss; Laith J Abu-Raddad
Journal:  J Int AIDS Soc       Date:  2015-07-28       Impact factor: 5.396

Review 8.  Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States.

Authors:  Elana S Rosenthal; Camilla S Graham
Journal:  Infect Agent Cancer       Date:  2016-05-16       Impact factor: 2.965

9.  Molecular characterization of Hepatitis C virus 3a in Peshawar.

Authors:  Amina Gul; Nabeela Zahid; Jawad Ahmed; Fazli Zahir; Imtiaz Ali Khan; Ijaz Ali
Journal:  BMC Infect Dis       Date:  2016-04-18       Impact factor: 3.090

10.  Drug Pricing Evolution in Hepatitis C.

Authors:  Nathalie Vernaz; François Girardin; Nicolas Goossens; Urs Brügger; Marco Riguzzi; Arnaud Perrier; Francesco Negro
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.